Background: Benzodiazepine poisoning is a frequent cause of emergency department (ED) visits, often related to suicide attempts. Flumazenil is the only specific antidote, but its continuous infusion protocol remains controversial because of its uncertain outcome benefits and increased risk of adverse events. This study aimed to evaluate the effect of continuous flumazenil infusion on the time to recovery of consciousness and secondary outcomes in patients with benzodiazepine poisoning stratified by hospitalization status. Methods: A retrospective cohort study was conducted at a tertiary hospital in Seoul, Korea, including adults treated for benzodiazepine poisoning in the ED between April 2019 and March 2024. The primary outcome being the time from arrival at the ED to regaining consciousness. Multivariate regression identified independent predictors of delayed recovery. Results: Among the 370 patients, 52.4% were hospitalized. Flumazenil infusion was administered in 46.8% of the patients, more often in hospitalized patients. In this group, flumazenil infusion significantly reduced the median time to regain consciousness (13.7 vs. 19.4 h, p = 0.006) but did not affect the overall hospital stay. In nonhospitalized patients, flumazenil infusion did not shorten the awakening time or prolong the ED stay. Adverse events, mainly agitation, were more frequent with flumazenil infusion. Conclusions: Continuous infusion of flumazenil accelerates the recovery of consciousness only in hospitalized patients who are severely affected by benzodiazepine poisoning but with increased adverse events and no reduction in hospital stay. Individualized patient selection and evidence-based protocols are needed for optimal and safe antidote use.

Background/Objectives: Some patients with severe hypoxic–ischemic brain injury after out-of-hospital cardiac arrest (OHCA) progress toward brain death, a trajectory not adequately captured by the conventional classification of favorable versus unfavorable neurological outcomes. We developed and internally evaluated a multimodal model combining quantitative brain computed tomography (CT), serum neuron-specific enolase (NSE) at 48 h, and clinical variables to predict operationally defined progression toward brain death (PTBD). Methods: This multicenter retrospective secondary analysis used prospectively collected data from the Korean Hypothermia Network registry. Adult comatose OHCA survivors treated with targeted temperature management between October 2015 and December 2020 were included. Multivariable logistic regression models were developed in the total cohort and in patients with poor neurological outcomes. Model performance was assessed using discrimination, calibration, the Brier score, and bootstrap internal validation. Results: Of 468 patients assessed, 376 were included; their mean age was 58.7 years, and 269 (71.5%) were male. Seventy-four patients (19.7%) met the operational definition of PTBD. In the total cohort, younger age, non-shockable rhythm, low gray-to-white matter ratio (GWR ≤ 1.19), and higher NSE at 48 h were independently associated with PTBD. Among 288 patients with poor neurological outcomes, younger age, low GWR, and higher NSE at 48 h remained independent predictors. The total-cohort model had an AUC of 0.895 and an optimism-corrected AUC of 0.890. Its AUC was higher than that of NSE at 48 h (p < 0.001) but not significantly different from that of GWR alone (p = 0.054). In the poor-outcome subgroup, the model had an AUC of 0.864 and an optimism-corrected AUC of 0.858 and significantly outperformed both GWR (p = 0.012) and NSE at 48 h (p < 0.001). Conclusions: PTBD represents a clinically distinguishable trajectory among patients with poor neurological outcomes after OHCA. A multimodal model using information available within 48 h demonstrated good internally validated performance and may support early risk stratification before definitive neuroprognostication. External validation is required before clinical implementation.